University of Oklahoma-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

    Lung Cancer, Vol. 155, pp. 151-155